Drug intelligence / Profile preview

oxytocin + methylergonovine + carboprost

Development stage
Unknown
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular, Intramyometrial
01

Overview

This is a combination of three uterotonic agents—oxytocin, methylergonovine, and carboprost—used in the management of postpartum hemorrhage (PPH) due to uterine atony. - **Oxytocin** is a peptide hormone that stimulates uterine smooth muscle contraction by acting as an agonist at the oxytocin receptor. It is considered the first-line agent for restoring uterine tone and preventing or treating PPH. - **Methylergonovine** is an ergot alkaloid that acts primarily as an agonist at serotonin and alpha-adrenergic receptors on uterine smooth muscle, causing sustained contractions. It serves as a second-line agent when oxytocin alone is insufficient but carries risks such as hypertension and vasoconstriction. - **Carboprost** is a synthetic prostaglandin F2α analog that induces myometrial contractions via prostaglandin F receptor activation; it also serves as a second-line agent for refractory cases but may cause bronchospasm or gastrointestinal side effects. The combination may be used sequentially or together in severe cases of PPH unresponsive to monotherapy, with each drug targeting different pathways to maximize efficacy in restoring uterine tone[1][3][5].

02

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD (Dopamine receptors)Oxytocin receptorADRA1A (α1A)PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on oxytocin + methylergonovine + carboprost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxytocin + methylergonovine + carboprost.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call